

## Special Issue

# Women's Special Issue Series: Pharmacoepidemiology

### Message from the Guest Editors

We are pleased to announce a Special Issue entitled "Women's Special Issue Series: Pharmacoepidemiology" to celebrate and highlight the achievements of women in the development of pharmacoepidemiology, the key research area spanning clinical pharmacology and epidemiology. We look forward to receiving your contributions.

---

### Guest Editors

Dr. Carlotta Franchi  
Prof. Dr. Li-Chia Chen  
Dr. Carlotta Lunghi

---

### Deadline for manuscript submissions

30 June 2026



**Pharmacoepidemiology**

---

an Open Access Journal  
by MDPI

---

Indexed in Scopus  
Tracked for Impact Factor



[mdpi.com/si/231253](https://mdpi.com/si/231253)

*Pharmacoepidemiology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmacoepidemiology@mdpi.com](mailto:pharmacoepidemiology@mdpi.com)

[mdpi.com/journal/  
pharmacoepidemiology](https://mdpi.com/journal/pharmacoepidemiology)





## Pharmacoepidemiology

---

an Open Access Journal  
by MDPI

---

Indexed in Scopus  
Tracked for Impact Factor



[mdpi.com/journal/  
pharmacoepidemiology](https://mdpi.com/journal/pharmacoepidemiology)



# About the Journal

## Message from the Editor-in-Chief

We are very proud to launch this new, international, peer-reviewed, and open access journal. The main aim of *Pharmacoepidemiology* is to publish novel and up-to-date research findings, reviews, and communications on the beneficial effects of drugs as well as their potential adverse effects on humans through epidemiological studies conducted in the real world on large populations.

All researchers working in the pharmacoepidemiologic field—such as epidemiologists, clinical researchers, pharmacologists, clinicians, and biostatisticians—are welcome to contribute to *Pharmacoepidemiology*.

---

## Editor-in-Chief

Dr. Carlotta Franchi

Laboratory of Pharmacoepidemiology and Human Nutrition,  
Department of Health Policy, Istituto di Ricerche Farmacologiche Mario  
Negri IRCCS, Milan, Italy

---

## Author Benefits

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### High Visibility:

indexed within ESCI (Web of Science), Scopus and other databases.

### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.3 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the second half of 2025).